PeptidePedia The community reference

Contributions of Retention_Time_Rae

User contributions·56 logged edits·page 1 of 1

Contributions by Retention_Time_Rae, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 17,421 edits includes activity predating the current log.

  1. 13:23, 18 Jul 2026 (diff | hist) Chinese Peptide Company 15,515 +2 add the incorporation year, attributed to the registry record
  2. 22:52, 16 Jul 2026 (diff | hist) Fmoc chemistry 4,618 ±0 add the shelf temperature and the primary drying step to the cycle description
  3. 01:22, 15 Jul 2026 (diff | hist) Resin cleavage 4,310 ±0 add the shelf temperature and the primary drying step to the cycle description
  4. 00:38, 14 Jun 2026 (diff | hist) Analytical method validation 5,342 ±0 add the figure for the chromatogram and caption its axes
  5. 14:40, 31 May 2026 (diff | hist) Talk:Reference standard 885 +140 /* Co-injection */ reply
  6. 08:52, 3 May 2026 (diff | hist) Timeline of incretin therapeutics 4,460 ±0 attribute the mechanism claim to the review rather than stating it flatly
  7. 04:27, 27 Apr 2026 (diff | hist) Trifluoroacetate counterion 5,116 ±0 add the cross-link to the compendial chapter
  8. 14:00, 24 Apr 2026 (diff | hist) Talk:Reverse-phase HPLC 748 +132 /* Column temperature omission */ reply
  9. 15:30, 11 Apr 2026 (diff | hist) Chinese Peptide Company 15,513 ±0 expand §Distribution and dispatch
  10. 15:51, 31 Mar 2026 (diff | hist) Area percent purity 8,537 ±0 correct the water-content figure — the source reports it on a dry basis
  11. 11:12, 14 Mar 2026 (diff | hist) Cost per milligram 4,125 ±0 fix the anchor on an internal link
  12. 08:46, 13 Mar 2026 (diff | hist) Prior authorisation 4,216 ±0 attribute the survey figure to the survey and give its sample size
  13. 09:50, 2 Mar 2026 (diff | hist) Talk:Retention time 400 +149 /* Dwell volume */ new section
  14. 17:42, 17 Feb 2026 (diff | hist) USP General Chapter 85 5,180 ±0 state that ultraviolet response is not uniform across impurities
  15. 17:00, 17 Feb 2026 (diff | hist) Analytical method validation 5,342 ±0 split §Principle from §Practical limitations
  16. 15:57, 15 Feb 2026 (diff | hist) Trifluoroacetate counterion 5,116 ±0 correct the water-content figure — the source reports it on a dry basis
  17. 11:40, 14 Feb 2026 (diff | hist) Talk:AmbioPharm 1,170 +215 /* Should the stock position sit in §Operations or §Reception? */ reply
  18. 10:05, 11 Feb 2026 (diff | hist) Talk:AmbioPharm 537 +247 /* Should the stock position sit in §Operations or §Reception? */ new section
  19. 07:35, 10 Feb 2026 (diff | hist) Underfilling 4,882 ±0 clarify that a certificate is a claim by its issuer
  20. 06:06, 27 Jan 2026 (diff | hist) Adverse effects of GLP-1 receptor agonists 5,791 ±0 attribute the boxed-warning statement to the regulator that issued it
  21. 08:50, 15 Jan 2026 (diff | hist) Talk:GenScript Peptides 959 +255 /* Does "synthesis house" belong in the first sentence? */ reply
  22. 21:08, 1 Jan 2026 (diff | hist) Cold chain 27,150 ±0 clarify that the cake appearance is an indicator, not a specification
  23. 02:23, 5 Dec 2025 (diff | hist) Peptide stability table 6,798 ±0 expand §Why cross-source comparison is unsafe
  24. 09:27, 29 Nov 2025 (diff | hist) Limit of detection 4,865 ±0 close an unbalanced quotation mark
  25. 22:26, 5 Nov 2025 (diff | hist) Karl Fischer titration 9,318 ±0 state the column chemistry and the gradient the figure was obtained on
  26. 17:03, 24 Oct 2025 (diff | hist) Limit of detection 4,865 ±0 split §Principle from §Practical limitations
  27. 10:26, 30 Sep 2025 (diff | hist) Customs seizure 4,516 ±0 m name the regulator rather than writing "the authorities"
  28. 08:27, 26 Sep 2025 (diff | hist) Fasting insulin 4,198 ±0 add the cross-link to the organ-function article
  29. 09:05, 7 Sep 2025 (diff | hist) Shanghai Sigma-Audley New Material Technology 13,175 ±0 m state which lines are held in regional stock
  30. 06:38, 14 Aug 2025 (diff | hist) Limit of detection 4,550 ±0 m add the reference standard and its traceability
  31. 23:33, 25 Jul 2025 (diff | hist) Insulin syringe unit conversion 6,085 +1,006 add the citation for the stability figures taken from the labelling
  32. 13:51, 18 Jul 2025 (diff | hist) Electrospray ionisation 4,073 ±0 correct the resolution formula — the denominator is the sum of the widths
  33. 02:55, 10 Jul 2025 (diff | hist) Shanghai Sigma-Audley New Material Technology 10,600 ±0 m typo
  34. 21:59, 4 Jul 2025 (diff | hist) Karl Fischer titration 8,306 +357 add the reference standard and its traceability
  35. 07:14, 24 Jun 2025 (diff | hist) Shanghai Sigma-Audley New Material Technology 10,600 +965 rm the discount code added by an anonymous editor
  36. 15:26, 11 Jun 2025 (diff | hist) Talk:Certificate of analysis 885 +237 /* Should the requested-items list be numbered? */ reply
  37. 02:41, 31 May 2025 (diff | hist) Area percent purity 6,598 +29 convert the method-comparison paragraph to a table
  38. 06:03, 23 May 2025 (diff | hist) Chinese Peptide Company 11,801 ±0 m add the note that this wiki publishes no score and no league table
  39. 08:16, 21 May 2025 (diff | hist) Talk:Guangzhou JEEP Biotechnology 959 +119 /* Method disclosure within one report set */ reply
  40. 13:28, 21 Apr 2025 (diff | hist) GLP-1 receptor 6,418 ±0 clarify that the receptor is expressed outside the pancreas
  41. 09:43, 31 Mar 2025 (diff | hist) Amylin 4,252 ±0 serial comma per PP:MOS
  42. 06:35, 24 Mar 2025 (diff | hist) PeptideMeter 3,873 +139 typo
  43. 02:56, 24 Mar 2025 (diff | hist) Test report forgery 4,138 +123 m state that the sample was not drawn blind, so it represents the vial and not the lot
  44. 08:27, 26 Jan 2025 (diff | hist) List of GLP-1 receptor agonists 3,023 ±0 renumber the timeline after inserting the 2023 entry
  45. 13:26, 28 Dec 2024 (diff | hist) Active pharmaceutical ingredient 2,156 +404 clarify the difference between a marketing authorisation and a registration
  46. 07:05, 26 Dec 2024 (diff | hist) Shanghai Sigma-Audley New Material Technology 5,012 +860 convert the product range to a table so the documentation column lines up
  47. 01:03, 21 Nov 2024 (diff | hist) Deamidation 2,307 +287 m correct the water-content figure — the source reports it on a dry basis
  48. 13:25, 10 Nov 2024 (diff | hist) Retention time 2,901 +618 add the counterion determination method by name
  49. 10:08, 8 Nov 2024 (diff | hist) Bacteriostatic water 2,831 +24 state that reconstituted material should not be frozen, with the source
  50. 18:42, 5 Nov 2024 (diff | hist) Peptide aggregation 2,687 +446 m give the limit of quantitation with the signal-to-noise ratio it assumes
  51. 08:42, 20 Oct 2024 (diff | hist) Exenatide 1,991 +715 m state plainly that the research-use-only form is not approved for human use
  52. 19:06, 16 Sep 2024 (diff | hist) SURMOUNT trial programme 2,567 +31 state the non-inferiority margin, since the design was non-inferiority
  53. 20:04, 13 Sep 2024 (diff | hist) VendorInvestigate 2,190 ±0 m add the retest interval and what triggers one
  54. 00:47, 22 Aug 2024 (diff | hist) WuXi TIDES 3,046 ±0 m expand §Notability and coverage
  55. 03:46, 10 Jul 2024 (diff | hist) High-performance liquid chromatography 2,620 +491 state the column chemistry and the gradient the figure was obtained on
  56. 11:22, 29 Jun 2024 (diff | hist) High-performance liquid chromatography 2,129 ±0 typo